[Cl:1][C:2]1[CH:3]=[N:4][C:5]2[NH:6][C:7]3[CH:8]=[C:9]([C:26](O)=[O:27])[CH:10]=[C:11]([CH:25]=3)[O:12][CH2:13][CH2:14][S:15][C:16]3[CH:24]=[C:20]([NH:21][C:22]=1[N:23]=2)[CH:19]=[CH:18][CH:17]=3.[CH2:29]([NH2:36])[C:30]1[CH:35]=[CH:34][CH:33]=[CH:32][CH:31]=1.C(N(CC)C(C)C)(C)C.F[P-](F)(F)(F)(F)F.N1(OC(N(C)C)=[N+](C)C)C2C=CC=CC=2N=N1.[C:70]([OH:76])([C:72]([F:75])([F:74])[F:73])=[O:71]>CN(C)C=O.CO>[F:73][C:72]([F:75])([F:74])[C:70]([OH:76])=[O:71].[CH2:29]([NH:36][C:26]([C:9]1[CH:10]=[C:11]2[CH:25]=[C:7]([CH:8]=1)[NH:6][C:5]1=[N:23][C:22](=[C:2]([Cl:1])[CH:3]=[N:4]1)[NH:21][C:20]1=[CH:24][C:16](=[CH:17][CH:18]=[CH:19]1)[S:15][CH2:14][CH2:13][O:12]2)=[O:27])[C:30]1[CH:35]=[CH:34][CH:33]=[CH:32][CH:31]=1A solution of 6-chloro-17-oxa-14-thia-2,4,8,24-tetraazatetracyclo[16.3.1.1(3,7).1(9,13)]tetracosa-1(22),3(24),4,6,9(23),10,12,18,20-nonaene-20-carboxylic acid (30 mg, 72 μmol) and benzylamine (12 μL, 0.11 mmol) in N,N-dimethylformamide (1 mL) was treated with N,N-diisopropylethylamine (50 μL, 0.29 mmol) followed by 0.5 M O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate in N,N-dimethylformamide (0.19 mL, 94 μmol) and stirred at 20° C. for 16 h. The reaction mixture was diluted with methanol (4.9 mL) and TFA (0.1 mL) and the resultant suspension was filtered. The filtrate was purified by preparative LCMS to give the desired product (7 mg, 16%) as a solid. LCMS for C26H23ClN5O2S (M+H)+: m/z=503.9. 1H NMR (300 MHz, DMSO-d6): δ 9.66 (s, 1H), 8.91-8.88 (m, 2H), 8.18 (s, 1H), 7.96 (d, J=5.6 Hz, 2H), 7.37-7.21 (m, 9H), 6.94 (s, 1H), 4.41 (d, J=5.9 Hz, 2H), 4.16-4.11 (m, 2H), 3.28-3.23 (m, 2H).
読み込み中…